Michael Barbella, Managing Editor05.10.24
Juniper Biomedical has completed an oversubscribed $2 million Series Seed financing and been awarded $1 million through the NIH Common Fund as a winner of the NIH SPARC Neuromod Prize, a competition designed to accelerate the development of targeted neuromodulation therapies.
The funding round, led by Auroral Holdings—a medtech-focused family office—with participation from Atma Capital, Hub Angels, Beacon Angels, and other private investors, will enable Juniper Biomedical to complete numerous development and commercialization milestones for its platform neuromodulation technology. The company's first application will offer long-term, precision therapy for patients with mixed urinary incontinence (MUI), which affects nearly one in three women.
"We are thrilled to have the support and confidence of our investors and NIH as we embark on the next phase of our journey to offer patients better care options," Juniper Biomedical Co-Founder/CEO David Constantine said. "Our team will leverage these new funds to accelerate the development of transformative solutions for multiple care gaps in pelvic health.”
Juniper Biomedical executives expect the new capital to fuel the company's expansion plans and help solidify its position in the neuromodulation solution ecosystem.
"We believe Juniper Biomedical has tremendous potential for growth and disruption in pelvic health in the historically underserved patient populations," Auroral Holdings Founder Larry Derose stated. “We are excited to partner with the company and look forward to supporting the team’s vision and innovation."
Juniper Biomedical is developing therapies for people suffering from pelvic health conditions like urinary incontinence, bowel incontinence, pelvic pain, sexual dysfunction, and pelvic floor disorders. Its solutions leverage a precise, low-power neuromodulation micro-implant that delivers a unique type of therapy to pelvic nerves. The firm's technology modulates distal target nerves locally, stimulating only the target and with far greater control over energy delivery. The system delivers therapy with extremely low energy into tissue and couples directly to the distal nerve, delivering energy in the most efficient way, selectively stimulating only the target.
The funding round, led by Auroral Holdings—a medtech-focused family office—with participation from Atma Capital, Hub Angels, Beacon Angels, and other private investors, will enable Juniper Biomedical to complete numerous development and commercialization milestones for its platform neuromodulation technology. The company's first application will offer long-term, precision therapy for patients with mixed urinary incontinence (MUI), which affects nearly one in three women.
"We are thrilled to have the support and confidence of our investors and NIH as we embark on the next phase of our journey to offer patients better care options," Juniper Biomedical Co-Founder/CEO David Constantine said. "Our team will leverage these new funds to accelerate the development of transformative solutions for multiple care gaps in pelvic health.”
Juniper Biomedical executives expect the new capital to fuel the company's expansion plans and help solidify its position in the neuromodulation solution ecosystem.
"We believe Juniper Biomedical has tremendous potential for growth and disruption in pelvic health in the historically underserved patient populations," Auroral Holdings Founder Larry Derose stated. “We are excited to partner with the company and look forward to supporting the team’s vision and innovation."
Juniper Biomedical is developing therapies for people suffering from pelvic health conditions like urinary incontinence, bowel incontinence, pelvic pain, sexual dysfunction, and pelvic floor disorders. Its solutions leverage a precise, low-power neuromodulation micro-implant that delivers a unique type of therapy to pelvic nerves. The firm's technology modulates distal target nerves locally, stimulating only the target and with far greater control over energy delivery. The system delivers therapy with extremely low energy into tissue and couples directly to the distal nerve, delivering energy in the most efficient way, selectively stimulating only the target.